Cost-effectiveness of family psychoeducation to prevent relapse in major depression: Results from a randomized controlled trial

BMC Psychiatry

Volumn 12, Issue , 2012, Pages

  Shimodera, Shinji ^a   Furukawa, Toshi A ^b   Mino, Yoshio ^c   Shimazu, Kae ^a   Nishida, Atsushi ^d   Inoue, Shimpei ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Mino Clinic   (Japan)

^d TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FAMILY THERAPY; FEMALE; HEALTH ECONOMICS; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; OUTCOME ASSESSMENT; PSYCHOEDUCATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; FAMILY CENTERED CARE; NATIONAL HEALTH INSURANCE; PROBLEM SOLVING; RELAPSE;

ADULT; AGED; COST-BENEFIT ANALYSIS; DEPRESSIVE DISORDER, MAJOR; FAMILY THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT EDUCATION AS TOPIC; PROBLEM SOLVING; RECURRENCE; TREATMENT OUTCOME;

EID: 84860806735     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-12-40     Document Type: Article

References (20)

1. Demyttenaere K, Bruffaerts R, Posada-Villa J, Gasquet I, Kovess V, Lepine JP, Angermeyer MC, Bernert S, de Girolamo G, Morosini P, et al. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA 2004, 291(21):2581-2590.
2. Furukawa TA, Kitamura T, Takahashi K. Time to recovery of an inception cohort with hitherto untreated unipolar major depressive episodes. Br J Psychiatry 2000, 177:331-335. 10.1192/bjp.177.4.331, 11116774.
3. Kanai T, Takeuchi H, Furukawa TA, Yoshimura R, Imaizumi T, Kitamura T, Takahashi K. Time to recurrence after recovery from major depressive episodes and its predictors. Psychol Med 2003, 33(5):839-845. 10.1017/S0033291703007827, 12877398.
4. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008, 358:252-260. 10.1056/NEJMsa065779, 18199864.
5. Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, Goodwin GM. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003, 361(9358):653-661. 10.1016/S0140-6736(03)12599-8, 12606176.
6. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006, 163(1):28-40. 10.1176/appi.ajp.163.1.28, 16390886.
7. Shimazu K, Shimodera S, Mino Y, Nishida A, Kamimura N, Sawada K, Fujita H, Furukawa TA, Inoue S. Family psychoeducation for major depression: randomised controlled trial. Br J Psychiatry 2011, 198:385-390. 10.1192/bjp.bp.110.078626, 21343330.
8. Pharoah F, Mari J, Rathbone J, Wong W. Family intervention for schizophrenia. Cochrane Database Syst Rev 2010, (12):CD000088.
9. Xia J, Merinder LB, Belgamwar MR. Psychoeducation for schizophrenia. Cochrane Database Syst Rev 2011(6):CD002831.
10. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Association, Washington, D.C., 4, American Psychiatric Association.
11. Folstein MF, Folstein SE, McHugh PR. " Mini-mental state" . A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12(3):189-198. 10.1016/0022-3956(75)90026-6, 1202204.
12. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967, 6(4):278-296. 10.1111/j.2044-8260.1967.tb00530.x, 6080235.
13. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961, 4:561-571. 10.1001/archpsyc.1961.01710120031004, 13688369.
14. Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be analysed?. BMJ 2000, 320(7243):1197-1200. 10.1136/bmj.320.7243.1197, 1127588, 10784550.
15. Fenwick E, Byford S. A guide to cost-effectiveness acceptability curves. Br J Psychiatry 2005, 187:106-108. 10.1192/bjp.187.2.106, 16055820.
16. Pyne JM, Tripathi S, Williams DK, Fortney J. Depression-free day to utility-weighted score: is it valid?. Med Care 2007, 45(4):357-362. 10.1097/01.mlr.0000256971.81184.aa, 17496720.
17. Pyne JM, Fortney JC, Tripathi S, Feeny D, Ubel P, Brazier J. How bad is depression? Preference score estimates from depressed patients and the general population. Health Serv Res 2009, 44(4):1406-1423. 10.1111/j.1475-6773.2009.00974.x, 2739035, 19453391.
18. McCrone P, Knapp M, Proudfoot J, Ryden C, Cavanagh K, Shapiro DA, Ilson S, Gray JA, Goldberg D, Mann A, et al. Cost-effectiveness of computerised cognitive-behavioural therapy for anxiety and depression in primary care: randomised controlled trial. Br J Psychiatry 2004, 185:55-62. 10.1192/bjp.185.1.55, 15231556.
19. Sado M, Yamauchi K, Kawakami N, Ono Y, Furukawa TA, Tsuchiya M, Tajima M, Kashima H. Cost of depression among adults in Japan in 2005. Psychiatry Clin Neurosci in press.
20. Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA, Corey-Lisle PK. The economic burden of depression in the United States: how did it change between 1990 and 2000?. J Clin Psychiatry 2003, 64(12):1465-1475. 10.4088/JCP.v64n1211, 14728109.